EPCAM and cancer: On these bases we believe that exosome analysis focused on EpCAM could prove to be potentially useful both as as prognostic factor or as a target for new treatment modalities in metastatic pancreatic cancer patients since drugs such as Edrecolomab and Catumaxomab, targeting EpCAM, are currently under investigation in a series of cancer types) [28].